Jakob Dupont, MD MA

Encouraging new data in JITC highlight the potential of botensilimab + balstilimab ( #BOT + #BAL ) to deliver deep and durable responses in women with heavily pretreated, platinum-refractory ovarian cancer—an area of profound unmet need. These results reinforce the power of Fc-enhanced CTLA-4 combined with PD-1 blockade to re-engage antitumor immunity in tumors historically considered resistant to immunotherapy. Grateful to the patients, investigators, and teams who made this work possible—and to the journal for helping advance the conversation around next-generation immuno-oncology. 📄 Publication: https://bit.ly/48MPgyD 📄 Press release: https://bit.ly/3KSL3Qw #OvarianCancer #ImmunoOncology #CTLA4 #PD1 #JITC #CancerResearch #Biotech

30

1 Comment

Managing BTK inhibitor related adverse events just got easier. Explore our new Interactive Decision Support Tool, built to guide you through real-world strategies for assessing and managing adverse events in patients with hematologic malignancies. 🔹 Expert insights from international leaders 🔹 Practical, scenario-based guidance 🔹 Focused on BTK inhibitor therapy This tool helps support confident, informed decision-making. ➡ Start using it here: https://bit.ly/448Rd59

6

Managing BTK inhibitor related adverse events just got easier. Explore our new Interactive Decision Support Tool, built to guide you through real-world strategies for assessing and managing adverse events in patients with hematologic malignancies. 🔹 Expert insights from international leaders 🔹 Practical, scenario-based guidance 🔹 Focused on BTK inhibitor therapy This tool helps support confident, informed decision-making. ➡ Start using it here: https://bit.ly/448Rd59

5

🧬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗮𝗿𝗴𝗲𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 #𝟭: 𝗞𝗥𝗔𝗦 - 𝗧𝗵𝗲 𝗨𝗹𝘁𝗶𝗺𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗖𝗼𝗺𝗲𝗯𝗮𝗰𝗸 𝗦𝘁𝗼𝗿𝘆 We're launching a new series diving into the hottest developments across key oncology targets. First up: KRAS research has absolutely exploded in 2024-2025, transforming from "undruggable" to one of the most exciting areas in cancer therapeutics. 🎯 𝗪𝗵𝗮𝘁'𝘀 𝗵𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴 𝗿𝗶𝗴𝗵𝘁 𝗻𝗼𝘄: 🚀 𝗧𝗵𝗿𝗲𝗲 𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 𝗶𝗻 𝟮𝟬𝟮𝟱 𝗮𝗹𝗼𝗻𝗲 - KRAS has gone mainstream  • Sotorasib + panitumumab: 148% improvement in colorectal cancer survival  • First-ever KRAS-targeted ovarian cancer therapy approved (44% response rates)  • Market projected to reach $2+ billion by 2030 🔬 𝗕𝗲𝘆𝗼𝗻𝗱 𝗚𝟭𝟮𝗖 - 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗳𝗿𝗼𝗻𝘁𝗶𝗲𝗿 𝗼𝗽𝗲𝗻𝘀 𝘂𝗽:  • KRAS G12D inhibitors finally showing clinical success (30% responses in pancreatic cancer!)  • Groundbreaking pan-KRAS degraders targeting 13 different mutations simultaneously (published in Science 2024)  • Revolutionary protein degradation strategies achieving what traditional inhibitors couldn't 💰 𝗠𝗮𝗷𝗼𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗺𝗼𝘃𝗲𝘀 𝘀𝗶𝗴𝗻𝗮𝗹 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲:  • Bristol Myers $5.8B acquisition of Mirati Therapeutics  • Revolution Medicines raised $823M for pan-KRAS approach  • 80+ KRAS inhibitors now in clinical trials across multiple variants 🔬 𝗧𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗺𝗼𝗱𝗲𝗹 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻:  • Patient-derived models showing 82-99% correlation with clinical outcomes  • GSK's "digital twin" technology creating AI-powered biological models  • Advanced organoids enabling precise drug testing and resistance prediction ⚡ 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗴𝗮𝗺𝗲:  • 75%+ response rates with rational combination approaches  • Real-time resistance monitoring via liquid biopsy (99.5% specificity)  • MD Anderson: KRAS + immunotherapy eliminating advanced pancreatic tumors in preclinical models 💡 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: The KRAS success story proves that even the most challenging targets can be conquered with the right models, persistence, and innovative approaches. For those developing KRAS inhibitors, 𝘁𝗵𝗲 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝗵𝗮𝘀 𝗻𝗲𝘃𝗲𝗿 𝗯𝗲𝗲𝗻 𝗺𝗼𝗿𝗲 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 to translating breakthrough science into clinical success. 𝘞𝘩𝘢𝘵'𝘴 𝘺𝘰𝘶𝘳 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘒𝘙𝘈𝘚 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩? 𝘈𝘳𝘦 𝘺𝘰𝘶 𝘴𝘦𝘦𝘪𝘯𝘨 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘣𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘴 𝘪𝘯 𝘺𝘰𝘶𝘳 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘳𝘦𝘢? 𝘚𝘵𝘢𝘺 𝘵𝘶𝘯𝘦𝘥 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘯𝘦𝘹𝘵 𝘱𝘰𝘴𝘵 𝘤𝘰𝘷𝘦𝘳𝘪𝘯𝘨 𝘌𝘎𝘍𝘙 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵𝘴! #KRAS #CancerResearch #DrugDiscovery #Oncology #Biotech #PreclinicalResearch #OncologyTargets

9

1 Comment

Navigating the competitive landscape of Acute Lymphocytic Leukemia (ALL)? The key to a winning commercial strategy lies beyond the initial diagnosis. At Prognos Health, we understand that granular lab data—from immunophenotyping to MRD testing—is the real roadmap. It helps you anticipate market needs and identify the right patients at the right time. Learn how to unlock these insights in our blog post: https://bit.ly/4nkqPwS #PrognosHealth #ALL #Oncology #Pharma #CommercialExcellence #HealthcareData #PatientJourney

6

We are excited to be presenting preclinical data on the first known BTK SH2 domain inhibitor (BTK SH2i) at #SIDSanDiego25! A BTK SH2i is an attractive therapeutic approach for B cell and mast cell-mediated inflammatory diseases, such as chronic spontaneous urticaria (CSU) and multiple sclerosis. We showed its potent BTK inhibition reduced skin inflammation in a model of CSU, and its high selectivity for BTK is differentiated compared to other approaches to inhibit BTK. These data are outlined in today’s press release: https://lnkd.in/eNFnx7eQ

90

1 Comment

OMG Freenome partnering with Roche to deploy onco ctDNA tests on Roche's new SBX sequencer outside the US. The deal is valued at $200M, Roche is also investing an additional $75M in Freenome: https://lnkd.in/gGCP8Gtg Shows that Roche is committed to the ctDNA (MRD & early detection) market and potentially leverages Roche's ex-US distribution and regulatory expertise advantage over Illumina. This comes just days after Roche did a shock'n'awe attack on Illumina at AMP. An early an early access customer (Hartwig, slide below) revealed that Axelios did great at tumor-normal cancer sequencing. Compared to Hartwig's production Illumina workflow, Roche delivered higher Q scores (46 vs 41), shorter turn around times, and more flexible batch sizes. But that's not all: AMP numbers imply that Axelios vs NovaSeq X: ≅2X read length 🤯 ≅2X reads per day 🤯🤯 ≅3X genomes per day, that's 62,000 per year 🤯🤯🤯 Beats Ultima Genomics, even Solaris Boost, as well. Still no news on Roche consumable costs but I know Josh Lauer and I'm sure he won't screw that up at AGBT (sorry Josh 🤣).

476

15 Comments

Radiopharmaceuticals, the next blockbuster frontier in oncology Congratulations to #Atkis Oncology for their successful IPO raising over $300M at a $1B valuation. Lilly's $100M check confirms big pharma's vote of confidence following multiple M&A transactions in the sector by Novartis, BMS, and AstraZeneca. Commercial success is there with Novartis‘ Pluvicto sales already trending $2B. Early clinical success is there with convincing data from Orano Med & AdvanCell at ESMO 2025. New clean & outpatient-friendly alpha therapies with #Astatine211 now promise further adoption of radiopharmaceuticals. Yutian Feng Milton Lönnroth Jeffrey Humphrey, MD Avi Veidman Patricia Zerr, PhD MBA Jean-Marc MENAT 🚀 jean-francois GESTIN Allan Marchington Blaine Robinson C. Ola Landgren, M.D., Ph.D. Stephanie Oestreich, PhD, MPA Stephen Nimer Manmeet Ahluwalia, MD, MBA, FASCO Josh Sharan Romain AfflelouMarc de Garidel Claude Bertrand John F. Heerdink, Jr.

121

1 Comment

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting https://lnkd.in/ghxp_kg8 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose study of VGA039 [...]

Zai Lab’s Bing Wan and Linda N Liu presented new data from studies evaluating two of our internally developed, next-generation investigational oncology therapies at #AACR25: ZL-6201, a novel antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/interleukin-12 (IL-12) immunocytokine for cancer immunotherapy. Read more about these potential first-in-class and best-in-class therapeutics: https://bit.ly/3YEOLBt #oncology #ADC #innovation #biotechnology #healthcare Also pictured: Nathan Ihle and Qidong Hu

48

Antibody-drug conjugates (ADCs) are reshaping oncology, but only about 24% of ADCs that reach Phase 3 ultimately succeed, underscoring how complex these therapies really are. As we move toward an integrated, data-driven approach that links real-world #multimodal data (clinical, genomic, transcriptomic, pathology), AI, and patient-derived organoids, the oncology drug development process will see improved target selection, optimized trial enrollment, and closed care gaps post-launch so the right patients actually receive these therapies. Here is a 3 minute read from Andy Moye, PhD @ Tempus AI (a leading AI and multimodal data company) that discusses the utility of a 30-gene RNA expression panel in the context of real world data to VIRTUALLY stratify responders and non-responders to an ADC. https://lnkd.in/gmPFeMzs

9

🔬 New Target RWE research is being presented at Paris-MASH 2025, titled “Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.” (Sanyal et al. 2025) Key takeaways from this analysis on Target RWE’s MASH cohort: • Higher baseline FIB-4 >2.67 was linked with markedly higher incidence of decompensation and increased risk of all-cause mortality (HR 6.02) and progression to cirrhosis (HR 5.48)—evidence that routine NITs can flag patients at elevated risk. • Worsening FIB-4 category over time tracked with higher rates of cirrhosis and a composite of serious clinical events vs. stable/improved trajectories—underscoring the value of longitudinal NIT monitoring. • Given biopsy’s limited use in routine care, NITs like FIB-4 can help assess disease severity and progression and inform risk-stratified management. 📈 These real-world findings support pragmatic risk stratification, smarter follow-up, and more targeted enrollment strategies in MASH studies. Read the study findings below and click the link to contact us today: https://lnkd.in/g3smEFDy #ParisMASH2025 #MASH #MASLD #Hepatology #RealWorldEvidence #OutcomesResearch #FIB4 #TargetRWE

9

NYC life sciences: what actually makes a company investable (right now): 🧬 A clear pathway named up front (IND → Ph1/2, 510(k)/De Novo/PMA, LDT/IVD with CLIA) and what must be true in the next 90–180 days. 🧬 Evidence design that travels: prospective where possible; endpoints that a payer or P&T committee respects. 🧬 GxP maturity appropriate to stage (GLP/CMC readiness for IND; design controls/ISO 13485 for devices; CLIA validation for Dx). 🧬 Critical quality attributes called out with a validation plan; supply risk and second-source thinking visible. 🧬 Payback windows and retention where applicable (Dx/DH/platform tools); early HEOR/real-world proxy for therapeutics. 🧬 Unit economics that hold outside the favorite segment; sensitivity on gross-margin drivers. 🧬 Named health-system/payer/IDN access (intro → pilot → scale), security/compliance cleared. 🧬 Use of proceeds mapped to de-risking milestones (e.g., tox complete, first-in-patient, CLIA validation, payer evidence package), not headcount optics. NYC advantage (why it matters here): 🔑 Dense access to academic medical centers, payers, and translational partners compresses time-to-“yes/no”—if your implementation, privacy, and validation are thought through. 🔑 Talent depth (clinical ops, CMC, regulatory, HEOR) allows fast iteration without leaving the customer. Fast killers: 📍 “Runway” talk without a risk-reduction plan. 📍 Roadmaps without owners/dates. 📍 Beautiful science with no path to coverage/coding or clinical adoption. 📍 Single-whale dependence (one PI, one site, one buyer). Bottom line: In New York, teams that publish these receipts get to a clean go/no-go faster. Everyone else cycles. #NYCLifeSciences #BiotechNYC #HealthTech #InvestorRelations

31

Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce two major developments that strengthen its ethnobotanical strategy: (i) its German partner CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, has secured exclusive rights (the "Distribution Agreement") to distribute Ritual Herbs, a premium line of German-crafted, herbal smoking blends developed by TFD GmbH.; and (ii) Neural has executed a new research agreement with Peru's national forestry authority, Servicio Nacional Forestal y de Fauna Silvestre ("SERFOR"), a key regulatory milestone in support of its mescaline-based drug development strategy. https://lnkd.in/dWkbYJt4

8